2023 Genitourinary oncology (GU) Cancer

ESMO 2023 GU Cancer Highlights – SunRISE-1, EV-302, PSMAfore

In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay:

– SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG – with TAR-200 mono therapy achieving 77% overall complete response rate

– EV-302 – Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Metastatic Urothelial Cancer, which showed impressive PFS and OS

– PSMAfore – 177Lu-PSMA-617 Versus Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer with impressive responsiveness

2023 ASCO

GI Cancer ASCO 2023 Highlights with Dr. Muhammad Shaalan Beg

Discussing GI (Gastrointestinal) Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Muhammad Shaalan Beg, Co-Leader Gastrointestinal Oncology, Adjunct Associate Professor of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center. Covering three important studies:

– PROSPECT: ph III trial of neoad chemoRT vs neoadj FOLFOX chemo with selective use of chemoRT, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC)

– NORPACT-1: Short-course neoadj FOLFIRINOX vs upfront surgery for resectable pancreatic head cancer

– NAPOLI 3: ph III trial in mets pancreatic ductal adenocarcinoma pts, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) vs nab-paclitaxel + gemcitabine

– IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) from the phase III IMbrave050 trial of adj atezo + bev vs active surveillance in pts with HCC


2023 ASCO

Lung Cancer ASCO 2023 Highlights with Dr. Charu Aggarwal

Discussing Lung Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies:

– ADAURA trial update with increase OS with adjuvant Osimertinib

– KEYNOTE 789 – Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant

– KEYNOTE 671 – Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

2023 ASCO

Breast Cancer ASCO 2023 Highlights with Dr. Stephanie Graff

Discussing Breast Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies:

– NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients

– SONIA challenging the need for first-line use of a CDK4/6 Inhibitor in HR+ advanced breast cancer patients

– X-7/7 trial evaluating fixed-dose capecitabine compared to standard dose capecitabine in metastatic breast cancer

Journal Club

EMERALD Ph III Study in discussion w/ Dr. Virginia Kaklamani (now FDA Approved)

Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with Dr. Virginia Kaklamani – Professor of Medicine – Leader of Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center.

Algorithms Gastrointestinal Cancer Journal

Colon Cancer Algorithm Discussion with Dr. Cathy Eng

Discussing the management of Colon Cancer using the algorithm with Dr. Cathy Eng, MD, Professor of Medicine at the Vanderbilt-Ingram Cancer Center, David H. Johnson Endowed Chair in Surgical & Medical Oncology, Co-Leader Gastrointestinal Cancer Research Program, Co-Director of GI Oncology Program.

2023 AACR

American Association for Cancer Research (AACR) 2023 Highlights from Community Oncology

Discussing AACR 2023 Highlights – focusing on 3 studies that potentially could impact our practice in the community from this conference.

– AEGEAN study for Non-Small Cell Lung Cancer

– Keynote 966 for Cholangiocarcinoma

– SWOG S1512 for Desmoplastic Melanoma

Algorithms Journal of Breast Cancer

HR+ Breast Cancer Management with Dr. Margaret Gatti-Mays

Discussing the management of Hormone Receptor Positive Breast Cancer with Dr. Margaret Gatti-Mays, Section Chief of the Breast Medical Oncology at the Ohio State University Comprehensive Cancer Center, The James Cancer Hospital & Solove Research Institute. In our discussion with Dr. Gatti-Mays we cover the treatment algorithm of the hormone receptor-positive disease following the FDA expanding the adjuvant abemaciclib approval where one doesn’t need Ki-67 levels anymore, and new agents recently approved by the FDA – elacestrant, TDXD and sacituzumab providing more treatment options for our patients.

Algorithms Journal of Breast Cancer

HR+ Invasive Lobular Carcinoma Management with Dr. Jason Mouabbi

Discussing the management of Invasive Lobular Carcinoma with Dr. Jason Mouabbi from the MD Anderson Cancer Center. We see different histologies in hormone receptor-positive breast cancer patients – we will focus on invasive lobular carcinoma in this video. Are these patients different than one with invasive ductal carcinoma? How does the prognosis differs?

Algorithms Journal of Breast Cancer

HER2+ Breast Cancer Algorithm Discussion with Dr. Paolo Tarantino

Discussing the management using an algorithm of HER 2 Neu Positive Breast Cancer – with Dr. Paolo Tarantino, European Institute of Oncology, Clinical Research Fellow at the Dana-Farber Cancer institute.

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology